Document Date. They serve as master regulators and signaling agents for metabolic pathways throughout the body. F: 617-441-6243 below): . . Document Details. View the AXLA U.S. Securities and Exchange Commission reporting information. SEC Filings SEC Filings Group. Create a list of the investments you want to track. MA 02139, O: 857-320-2200 3rd Floor, Cambridge, Business Wire. E: info@axcellatx.com, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Notifications. 10-Q Filing Date. Subscriber Agreement & Terms of Use, Insider Trades. Inside Axcella Health Inc.'s 10-K Annual Report: Other - Other Highlight. E: info@axcellatx.com. 8-K 1 axcella_06302019x8k.htm 8-K . Form. Quotemediais not affiliated with or approved by the U.S. Securities and Exchange Commission. Download DOC. Oct 17, 2022. This information can be used by investors to verify and understand the financial position of the company. Something went wrong while loading Watchlist. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. 3,4,5. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Financial Ratios. If you have questions about the Special Meeting or the proposals to be presented thereat, if you need additional copies of the proxy statement or the enclosed proxy card or if you would like copies of any of the Company's filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021, and our subsequent . AXLA Annual Reports. Manager Portfolios. AXLA Valuations. Financial Results: Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities totaled $25.4 million, compared to $55.0 million as of December 31, 2021. Type a symbol or company name. Home. We have built a strong leadership team with deep biopharma expertise. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Notice is hereby given that the 2022 Annual Meeting of Stockholders, or Annual Meeting, of Axcella Health Inc. (d/b/a Axcella Therapeutics) (the "Company" or "Axcella"), which will be a virtual-only meeting to be held on May 19, 2022, at 10:00 A.M. Eastern Time. E: info@axcellatx.com, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. Axcella Health Inc. (AXLA) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021. Pioneering a new approach to treating complex diseases using Endogenous Metabolic Modulators (EMMs). AXLA Annual Reports. Touch device users, explore by touch or with swipe gestures. Nasdaq provides companysSEC filings, which arefinancial statements andreports filed electronically with the U.S. Securities and Exchange Commission (SEC) byQuotemedia. Axcella Health Inc. SEC filings breakout by MarketWatch. 10-K Annual Report March 2022 10-K Annual Report March 2021 10-K Annual Report . Report of unscheduled material events or corporate event, Quarterly report which provides a continuing view of a company's financial position, Statement of changes in beneficial ownership of securities. View HTML. MA 02139, O: 857-320-2200 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the . 3rd Floor, Cambridge, EX-101.SCH - XBRL TAXONOMY . Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. Copyright 2022 MarketWatch, Inc. All rights reserved. Items per page. See AXA1125s potential impact on Long COVID, Read about AXA1125s Fast Track Designation in NASH, Learn about our EMMPACT clinical trial in NASH, See how compositions of endogenous metabolic modulators (EMMs) can be utilized for complex diseases. In September 2022, the Company received $6.0 million from the issuance of convertible notes to funds associated with Flagship Pioneering and, in October 2022, the . 0001104659-22-085175.pdf. Report of unscheduled material events or corporate event, Quarterly report which provides a continuing view of a company's financial position, Statement of changes in beneficial ownership of securities. Historical and current end-of-day data provided by FACTSET. F: 617-441-6243 We are publishing innovative research and presenting at leading conferences. MA 02139, O: 857-320-2200 Correspondence with the SEC 06/10/20 UPLOAD Letter from the SEC 06/10/20 EFFECT Notice of effectiveness 05/13/20 CORRESP . When autocomplete results are available use up and down arrows to review and enter to select. 2021 Quotemedia. Axcella Health Inc. (AXLA) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2022. . 0000899243-22-033691.xls. For the best MarketWatch.com experience, please update to a modern browser. EMMs encompass a broad set of molecular families, including amino acids and their derivatives. Type a symbol or company name. 0000899243-22-033691.rtf. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Have Watchlists? AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) . SEC Filings. Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3, 840 Memorial Drive, Copy and paste multiple symbols separated by spaces. AXLA Valuations. Issuer. Create your Watchlist to save your favorite quotes on Nasdaq.com. They serve as master regulators and signaling agents for metabolic pathways throughout the body. . This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8 . For financial reporting, their fiscal year ends on December 31st. Download PDF. The clinical data we have generated to date support the potential for our therapeutic product candidates to simultaneously influence multiple biologies relevant to complex diseases with a favorable safety profile. The purpose of the virtual Annual Meeting is the following: Financial Ratios. Axcella Health Inc. (AXLA) 10-K Annual Report Wed Mar 30 2022; . EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION . Filing year. Axcella Therapeutics. 0001104659-22-085175.rtf. SEC Filings. Financial Stability. View the AXLA U.S. Securities and Exchange Commission reporting information. Palantir stock falls after earnings as revenue growth slows, U.S. seizes Bitcoin once valued at $3.4 billion that real-estate developer stole from dark web a decade ago, The Powerball jackpot is now $1.9 billion, setting another record, The turkey is non-negotiable: Americans refuse to skimp on Thanksgiving Day turkey, despite soaring food prices. Log in to see them here or sign up to get started. Intraday data delayed at least 15 minutes or per exchange requirements. Initial filing by director officer or owner of more than ten percent. Axcella Health Inc. (AXLA) - DEFA14A - Additional Proxy Soliciting Materials (definitive) View HTML. EMMs encompass a broad set of molecular families, including amino acids and their derivatives. Date of Report (Date of earliest event reported): August 12, 2019 _____ AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) . Our lead product candidates are for liver diseases. Axcella Health Inc. (AXLA) SEC Filing 8-K Material Event for the period ending Tuesday, November 1, 2022. . All quotes are in local exchange time. Cookie Notice (). 8-K: Current Reports. Find the latest SEC Filings data for Axcella Health Inc. Common Stock (AXLA) at Nasdaq.com. Privacy Notice, and Initial filing by director officer or owner of more than ten percent. Intrinsic Value. Insider Trades. Axcella Health Inc. Filing Formats. There are currently no items in this Watchlist. These symbols will be available throughout the site during your session. Download XLS. However, if we or any of the third parties with whom we engage were to . XBRL Viewer. SEC filings and transcripts for Axcella Health Inc, including financials, news, proxies, indentures, prospectuses, . EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. Endogenous Metabolic Modulators, or EMMs, are a critical set of molecules that are fundamental to biology. Find out about Axcellas latest accomplishments and upcoming events. Statement of changes in beneficial ownership of securities. Diesel shortage keeps fuel prices high at the pump. Many, but not all SEC filings are available in the SECs EDGAR database. 2022, Nasdaq, Inc. All Rights Reserved. Financial Stability. Endogenous Metabolic Modulators. Notifications. Axcella's net loss for the quarter and nine months ended September 30, 2022, was $17.8 million, or $0.34 per basic and diluted share, and $58.2 million or $1.19 per share, respectively. Initial filing by director officer or owner of more than ten percent. SEC Filing Details SEC Filing Details. SEC Filings. Intrinsic Value. XBRL. Axcella Health Inc. - 10-Q, Quarterly Report-SEC Filings: Di: Axcella Health Inc. - 8-K, Current Report-SEC Filings: Di: Axcella Reports Third Quarter Financial Results and Provides Business . 4. Axcella Health Inc. is incorporated in the state of Delaware. Is that fair? Hes not willing to live in my house because it has fewer amenities: My boyfriend wants me to move in and pay half his monthly costs. 840 Memorial Drive, The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other areas of their business on a regular basis. Filing date Description Form Filing Group View; Aug 02, 2022: Report of unscheduled material events or corporate event. 3rd Floor, Cambridge, SEC Filings. Intraday Data provided by FACTSET and subject to terms of use. SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2022 2021 2020 2019 2018 2017 2016 2015 Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3, 840 Memorial Drive, Axcella Health Inc is primarely in the business of biological products (no diagnostic substances). This browser is no longer supported at MarketWatch. Axcella Health Inc. SEC filings breakout by MarketWatch. By using this site you agree to the 0001104659-22-085175.xls. We combine our deep understanding of metabolic pathways, our unique EMM-focused database and recent advances in technology and systems biology to design novel product candidates with the potential to have a profound impact on complex diseases and support health. We value bright minds, collaborative approaches and energetic spirits. 0000899243-22-033691.pdf. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 10-K Annual Report March 2022 10-K Annual Report March 2021 10-K Annual . Our net . F: 617-441-6243 Visit a quote page and your recently viewed tickers will be displayed here. Nov 1, 2022. Manager Portfolios. Endogenous Metabolic Modulators, or EMMs, are a critical set of molecules that are fundamental to biology. Do Not Sell My Personal Information (CA Residents Only).